{"id":2564678,"date":"2023-09-05T06:08:02","date_gmt":"2023-09-05T10:08:02","guid":{"rendered":"https:\/\/platoai.gbaglobal.org\/platowire\/clarissa-campbell-and-barbara-maier-awarded-erc-starting-grants-at-cemm\/"},"modified":"2023-09-05T06:08:02","modified_gmt":"2023-09-05T10:08:02","slug":"clarissa-campbell-and-barbara-maier-awarded-erc-starting-grants-at-cemm","status":"publish","type":"platowire","link":"https:\/\/platoai.gbaglobal.org\/platowire\/clarissa-campbell-and-barbara-maier-awarded-erc-starting-grants-at-cemm\/","title":{"rendered":"Clarissa Campbell and Barbara Maier awarded ERC Starting Grants at CeMM"},"content":{"rendered":"

\"\"<\/p>\n

Clarissa Campbell and Barbara Maier, two talented researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, have been awarded prestigious ERC Starting Grants. These grants are highly competitive and recognize outstanding early-career scientists who have the potential to make significant contributions to their respective fields.<\/p>\n

Clarissa Campbell, a group leader at CeMM, has been awarded the ERC Starting Grant for her research on the role of immune cells in neurodegenerative diseases. Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, are characterized by the progressive loss of neurons in the brain. Campbell’s research aims to understand how immune cells, specifically microglia, contribute to the development and progression of these diseases. By unraveling the complex interactions between immune cells and neurons, Campbell hopes to identify new therapeutic targets for the treatment of neurodegenerative diseases.<\/p>\n

Barbara Maier, also a group leader at CeMM, has been awarded the ERC Starting Grant for her research on the epigenetic regulation of gene expression. Epigenetics refers to changes in gene expression that do not involve alterations in the DNA sequence itself. Maier’s research focuses on understanding how epigenetic modifications influence gene expression patterns and contribute to the development of diseases, such as cancer. By deciphering the epigenetic code, Maier aims to uncover new insights into disease mechanisms and potentially identify novel therapeutic strategies.<\/p>\n

Both Campbell and Maier are highly accomplished scientists with impressive track records. Campbell completed her PhD in Immunology at the University of Cambridge and has since made significant contributions to the field of neuroimmunology. Her work has been published in top-tier scientific journals and has garnered international recognition. Maier, on the other hand, obtained her PhD in Molecular Biology from the University of Vienna and has conducted groundbreaking research on epigenetic regulation. Her work has shed light on the role of epigenetics in cancer development and has the potential to revolutionize cancer treatment.<\/p>\n

The ERC Starting Grants awarded to Campbell and Maier will provide them with the necessary funding and support to further their research endeavors. These grants are highly competitive, with only a small percentage of applicants receiving funding. The recognition from the European Research Council not only validates the quality and importance of their research but also opens up new opportunities for collaboration and scientific advancement.<\/p>\n

CeMM, as a leading research institution in molecular medicine, is proud to have two of its researchers receive such prestigious grants. The center is committed to fostering excellence in biomedical research and providing a supportive environment for scientists to thrive. The achievements of Campbell and Maier highlight the caliber of research being conducted at CeMM and its impact on advancing our understanding of human health and disease.<\/p>\n

In conclusion, Clarissa Campbell and Barbara Maier’s ERC Starting Grants are a testament to their exceptional research contributions and potential for future breakthroughs. Their work at CeMM will undoubtedly contribute to advancements in neurodegenerative diseases and epigenetic regulation, respectively. We congratulate them on this well-deserved recognition and look forward to the exciting discoveries they will make in the years to come.<\/p>\n